Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

Next Previous
Trial Profile

A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerebroside-sulfatase (Primary)
  • Indications Metachromatic leukodystrophy
  • Focus Therapeutic Use
  • Sponsors Shire

Most Recent Events

  • 26 Apr 2022 Using data from 3 studies (NCT00418561; NCT00633139; NCT00681811) were used to evaluate the toxic effects of sulfatide and lysosulfatide on the central (CNS) and peripheral (PNS) nervous systems in children with metachromatic leukodystrophy (MLD) and to explore the impact of treatment with intravenous recombinant human arylsulfatase A (rhASA) on myelin turnover, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
  • 07 May 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top